SCHEMBL31748682

SCHEMBL31748682

COC(=O)c1cn(COCC[Si](C)(C)C)c2cc(F)c(-c3ccc(C4(O)CCC4)cc3)c(F)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKAB2 O43741 6/20 0.44
▸ PRKAG1 P54619 6/20 0.44
▸ PRKAA2 P54646 6/20 0.44
▸ PRKAA1 Q13131 6/20 0.44
▸ PRKAG3 Q9UGI9 6/20 0.44
▸ PRKAG2 Q9UGJ0 6/20 0.44
▸ PRKAB1 Q9Y478 6/20 0.44
▸ SYK P43405 2/20 0.33
▸ EGFR P00533 1/20 0.31
▸ IGF1R P08069 1/20 0.31
▸ SRC P12931 1/20 0.31
▸ FLT4 P35916 1/20 0.31
▸ KDR P35968 1/20 0.31
▸ FLT3 P36888 1/20 0.31
▸ EPHB4 P54760 1/20 0.31
▸ TEK Q02763 1/20 0.31
▸ KIT P10721 2/20 0.31
▸ KLKB1 P03952 1/20 0.31
▸ PKM P14618 1/20 0.30
▸ LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31748660 0.91 PRKAB2 (0.43) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL31748528 0.79 PRKAB2 (0.38) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL31748692 0.78 DGAT1 (0.34) EGFRIGF1RSRCFLT4KDR
SCHEMBL31748696 0.75 PRKAB2 (0.37) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL31748691 0.72 DGAT1 (0.32) —
SCHEMBL31748766 0.71 PRKAB2 (0.37) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL31748550 0.71 DGAT1 (0.31) SYK
SCHEMBL31748640 0.69 DGAT1 (0.33) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL31748662 0.69 DGAT1 (0.38) EGFRIGF1RSRCFLT4KDR
SCHEMBL31748388 0.69 KLKB1 (0.35) EGFRIGF1RSRCFLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF BIOLEXIS THERAPEUTICS INC (US) 2025-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF PRKAB2, PRKAB1, PRKAR2B PRKAB2 1/4885PRKAG1 6/4885PRKAA2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback